Sandy Wong, MD

Title(s)Assistant Professor, Medicine
SchoolSchool of Medicine
Address400 Parnassus Avenue
San Francisco CA 94117
vCardDownload vCard

    Collapse Overview 

    Collapse Featured Content 
    Collapse Twitter

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Early Dynamics and Depth of Response in Multiple Myeloma Patients Treated With BCMA CAR-T Cells. Front Oncol. 2021; 11:783703. Wong SW, Shah N, Ledergor G, Martin T, Wolf J, Shui AM, Huang CY, Martinez-Lopez J. PMID: 34938662; PMCID: PMC8685203.
      View in: PubMed   Mentions:
    2. Outcomes of kidney transplant recipients with ESKD due to plasma cell dyscrasia: A case series. Clin Transplant. 2021 Nov 19; e14541. Dinh AR, Wong SW, Martin TG, Wolf JL, Webber AB. PMID: 34797567.
      View in: PubMed   Mentions:
    3. Feasibility of a Supportive Mobile Health App for Chimeric Antigen Receptor T-Cell Therapy. Blood. 2021 Nov 5; 138(Supplement 1):3009-3009. Banerjee BR, Sykes SB, Shah SN, Andreadis AC, Sayre SP, Martin MT, Shore SJ, Sodowick SA, Wong WS. .
      View in: Publisher Site   Mentions:
    4. Randomized Study of Digital Life Coaching during Autologous Stem Cell Transplantation. Blood. 2021 Nov 5; 138(Supplement 1):4023-4023. Banerjee BR, Lazar LA, Ryan RC, Knoche KJ, Brassil BK, Jackson JL, Patel PD, Lo LM, Arora AS, Chung CA, Wong WS, Wolf WJ, Martin MT, Dhruva DA, Shah SN. .
      View in: Publisher Site   Mentions:
    5. Anakinra Targeting Cytokine Release Syndrome Associated with Chimeric Antigen Receptor T-Cell Therapies. Blood. 2021 Nov 5; 138(Supplement 1):2812-2812. Wong WS, Richard RS, Lin LY, Madduri MD, Jackson JC, Zudaire ZE, Romanov RV, Trigg TM, Vogel VM, Garrett GA, Hullinger HL, Nesheiwat NT, Martin MT, Jagannath JS. .
      View in: Publisher Site   Mentions:
    6. Impact of Corticosteroids on Efficacy of BCMA Targeted CAR-T Therapy in Multiple Myeloma. Blood. 2021 Nov 5; 138(Supplement 1):1759-1759. Duvalyan DE, Lo LM, Martin MT, Wolf WJ, Chung CA, Arora AS, Shah SN, Huang HC, Wong WS. .
      View in: Publisher Site   Mentions:
    7. Evaluation of subcutaneous daratumumab injections in the ambulatory care setting. J Oncol Pharm Pract. 2021 Oct 14; 10781552211046911. Tam AH, Jung Y, Young R, Huang CY, Wolf J, Shah N, Wong SW, Martin TG, Lo M. PMID: 34647506.
      View in: PubMed   Mentions:    Fields:    
    8. Macrophage Activation Syndrome-Like Manifestations (MAS-L) Following BCMA-directed CAR T-cells in Multiple Myeloma. Blood Adv. 2021 Oct 13. Kennedy VE, Wong C, Huang CY, Kambhampati S, Wolf JL, Martin TG, Shah N, Wong SW. PMID: 34644387.
      View in: PubMed   Mentions:    Fields:    
    9. P-225: A first-in-human study of FOR46 in patients with triple refractory Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 2021 Oct 1; 21:s164. Wong WS, Imus IP, Mark MT, Kaufman KJ, Imus IA, Zonder ZJ, Walker WZ, Sherbenou SD, Schroeder SM, Abbey AJ, Nasoff NM, Dorr DA, Liu LB, Martin MT. .
      View in: Publisher Site   Mentions:
    10. Infectious complications in relapsed refractory multiple myeloma patients after BCMA Car t-cell therapy. Blood Adv. 2021 Sep 20. Kambhampati S, Sheng Y, Huang CY, Bylsma SA, Lo M, Kennedy VE, Natsuhara K, Martin T, Wolf JL, Shah N, Wong SW. PMID: 34543400.
      View in: PubMed   Mentions:    Fields:    
    11. Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma. J Hematol Oncol. 2021 08 17; 14(1):126. Martinez-Lopez J, Alonso R, Wong SW, Rios R, Shah N, Ruiz-Heredia Y, Sanchez-Pina JM, Sanchez R, Bahri N, Zamanillo I, Poza M, Buenache N, Encinas C, Juarez L, Miras F, Collado L, Barrio S, Martin T, Cedena MT, Wolf J. PMID: 34404440; PMCID: PMC8369640.
      View in: PubMed   Mentions:    Fields:    
    12. Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. N Engl J Med. 2021 07 01; 385(1):46-58. Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, Sanchorawala V, Gibbs S, Mollee P, Venner CP, Lu J, Schönland S, Gatt ME, Suzuki K, Kim K, Cibeira MT, Beksac M, Libby E, Valent J, Hungria V, Wong SW, Rosenzweig M, Bumma N, Huart A, Dimopoulos MA, Bhutani D, Waxman AJ, Goodman SA, Zonder JA, Lam S, Song K, Hansen T, Manier S, Roeloffzen W, Jamroziak K, Kwok F, Shimazaki C, Kim JS, Crusoe E, Ahmadi T, Tran N, Qin X, Vasey SY, Tromp B, Schecter JM, Weiss BM, Zhuang SH, Vermeulen J, Merlini G, Comenzo RL, ANDROMEDA Trial Investigators. PMID: 34192431.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    13. The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma. Transplant Cell Ther. 2021 Oct; 27(10):807-816. Holstein SA, Bahlis N, Bergsagel PL, Bhutani M, Bolli N, Brownstein C, Demolis P, Foureau D, Gay F, Ghobrial IM, Gormley N, Hillengass J, Kaiser M, Maus MV, Melenhorst JJ, Merz M, Dwyer MO, Paiva B, Pasquini MC, Shah N, Wong SW, Usmani SZ, McCarthy PL. PMID: 34107340; PMCID: PMC8478786.
      View in: PubMed   Mentions: Translation:Humans
    14. PRO21 Burden of Illness in Patients with Light Chain (AL) Amyloidosis: A Real World Study Using Optum Claims Database. Value in Health. 2021 Jun 1; 24:s201. D'Souza DA, Abonour AR, Zonder ZJ, Hoffman HJ, Wong WS, Liedtke LM, Dispenzieri DA, Cote CS, Nair NS, Potluri PR, Weiss WB, Vermeulen VJ, Lam LA, Mehra MM. .
      View in: Publisher Site   Mentions:
    15. PRO78 Real-World Treatment Patterns in Patients with Light Chain (AL) Amyloidosis: Analysis of the Optum US Electronic Health Records (EHR) and Commercial Claims Database. Value in Health. 2021 Jun 1; 24:s212. Dispenzieri DA, Zonder ZJ, Hoffman HJ, Wong WS, Liedtke LM, Abonour AR, D'Souza DA, Lee LC, Cote CS, Nair NS, Potluri PR, Weiss WB, Vermeulen VJ, Lam LA, Mehra MM. .
      View in: Publisher Site   Mentions:
    16. Feasibility of digital life coaching during stem cell transplantation for multiple myeloma. Journal of Clinical Oncology. 2021 May 20; 39(15_suppl):e24103-e24103. Banerjee BR, Huang HC, Dunn DL, Knoche KJ, Brassil BK, Jackson JL, Patel PD, Lo LM, Arora AS, Wong WS, Wolf WJ, Martin MT, Dhruva DA, Shah SN. .
      View in: Publisher Site   Mentions:
    17. Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma. Cancer. 2021 Jun 01; 127(11):1816-1826. Martin TG, Shah N, Richter J, Vesole DH, Wong SW, Huang CY, Madduri D, Jagannath S, Siegel DS, Biran N, Wolf JL, Parekh S, Cho HJ, Munster P, Richard S, Ziti-Ljajic S, Chari A. PMID: 33735504; PMCID: PMC8252002.
      View in: PubMed   Mentions: 1     Fields:    
    18. Early Time-to-Tocilizumab after B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy in Myeloma. Transplant Cell Ther. 2021 06; 27(6):477.e1-477.e7. Banerjee R, Marsal J, Huang CY, Lo M, Kambhampati S, Kennedy VE, Arora S, Wolf JL, Martin TG, Wong SW, Shah N. PMID: 33831353.
      View in: PubMed   Mentions: Translation:Humans
    19. 487 Patterns of Tocilizumab Use Among Myeloma Patients Receiving BCMA-Directed Therapies: Effect on Day 30 Outcomes. . 2021 Mar 1; 27(3):s398-s399. Marsal MJ, Banerjee BR, Huang HC, Lo LM, Kennedy KV, Arora AS, Wolf WJ, Martin MT, Wong WS, Shah SN. .
      View in: Publisher Site   Mentions:
    20. Benzodiazepine and zolpidem prescriptions during autologous stem cell transplantation. eJHaem. 2021 Feb 6. Banerjee BR, Lazar LA, Dunn DL, Knoche KJ, Lo LM, Arora AS, Wong WS, Wolf WJ, Martin MT, Dhruva DA, Shah SN. .
      View in: Publisher Site   Mentions:
    21. Supportive Care for Patients with Systemic Light Chain Amyloidosis. Hematol Oncol Clin North Am. 2020 12; 34(6):1177-1191. Wong SW, Fogaren T. PMID: 33099432.
      View in: PubMed   Mentions:
    22. Incidence, management and outcomes of arterial and venous thrombosis after chimeric antigen receptor modified T cells for B cell lymphoma and multiple myeloma. Leuk Lymphoma. 2021 04; 62(4):1003-1006. Parks AL, Kambhampati S, Fakhri B, Andreadis C, Gray L, Wong SW, Shah N, Fang MC. PMID: 33258699; PMCID: PMC8012226.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    23. Outcomes of Plasma Cell Leukemia Patients in the Era of Next-Generation Novel Agents: A Single-Center Retrospective Cohort Study. Blood. 2020 Nov 5; 136(Supplement 1):6-7. Ge GA, Huang HC, Martin MT, Wolf WJ, Shah SN, Wong WS. .
      View in: Publisher Site   Mentions:
    24. Incidence, Management and Outcomes of Arterial and Venous Thromboembolism after Chimeric Antigen Receptor Modified T Cells for B-Cell Lymphoma and Multiple Myeloma. Blood. 2020 Nov 5; 136(Supplement 1):7-7. Parks PA, Kambhampati KS, Fakhri FB, Andreadis AC, Gray GL, Wong WS, Shah SN, Fang FM. .
      View in: Publisher Site   Mentions:
    25. Real-World Treatment Patterns in Patients with Light Chain (AL) Amyloidosis: Analysis of the Optum US Electronic Health Records and Commercial Claims Database. Blood. 2020 Nov 5; 136(Supplement 1):4-5. Dispenzieri DA, Zonder ZJ, Hoffman HJ, Wong WS, Liedtke LM, Abonour AR, D'Souza DA, Lee LC, Nair NS, Potluri PR, Weiss WB, Vermeulen VJ, Lam LA, Mehra MM. .
      View in: Publisher Site   Mentions:
    26. Phase II Study of Daratumumab in Combination with Azacitidine and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Daratumumab: Darazadex. Blood. 2020 Nov 5; 136(Supplement 1):27-28. Kambhampati KS, Wong WS, Martin MT, Wolf WJ, Choudhry CP, Karlon KW, Wiita WA, Shah SN. .
      View in: Publisher Site   Mentions:
    27. Patterns of Tocilizumab Use Among Myeloma Patients Receiving Bcma-Directed Therapies: Effect on Day 30 Outcomes. Blood. 2020 Nov 5; 136(Supplement 1):5-6. Marsal MJ, Banerjee BR, Huang HC, Lo LM, Kennedy KV, Arora AS, Wolf WJ, Martin MT, Wong WS, Shah SN. .
      View in: Publisher Site   Mentions:
    28. Infectious Complications of BCMA-Targeted and CD19-Targeted Chimeric Antigen Receptor T-Cell Immunotherapy. Blood. 2020 Nov 5; 136(Supplement 1):4-5. Kambhampati KS, Fakhri FB, Sheng SY, Huang HC, Byslma BS, Natsuhara NK, Biswas BD, Lo LM, Ai AW, Kaplan KL, Martin MT, Wolf WJ, Shah SN, Andreadis AC, Wong WS. .
      View in: Publisher Site   Mentions:
    29. Making Clinical Decisions to Change Therapy Using Measurable Residual Disease Improves the Outcome in Multiple Myeloma. Blood. 2020 Nov 5; 136(Supplement 1):42-43. Martinez Lopez MJ, Alonso Fernández AR, Wong WS, Rios RR, Shah SN, Cedena Romero CM, Ruiz-Heredia RY, Sanchez SJ, Barrio Garcia BS, Martin MT, Wolf WJ. .
      View in: Publisher Site   Mentions:
    30. Association of Baseline and Postinfusion Biomarkers with Safety and Efficacy Endpoints in Patients Treated with Orvacabtagene Autoleucel (orva-cel; JCARH125) in the Phase 1/2 Evolve Study (NCT03430011). Blood. 2020 Nov 5; 136(Supplement 1):2-3. Piasecki PJ, Devries DT, Radhakrishnan RA, Li LY, Heipel HM, Fox FB, Beckett BV, Cota Stirner CM, Conte CK, Doerr DT, Mailankody MS, Wong WS, McCarthy MP. .
      View in: Publisher Site   Mentions:
    31. Macrophage Activation Syndrome-like Manifestations (MAS-L) Following BCMA-Directed CAR T-Cells in Multiple Myeloma. Blood. 2020 Nov 5; 136(Supplement 1):7-8. Kennedy KV, Wong WC, Huang HC, Wolf WJ, Martin MT, Shah SN, Wong WS. .
      View in: Publisher Site   Mentions:
    32. Modified Hyper-CVAD With Proteasome Inhibition for Multiple Myeloma: A Single-Center Retrospective Analysis. Clin Lymphoma Myeloma Leuk. 2020 12; 20(12):e961-e985. Narayan R, Galligan D, Lazar AA, Kim S, Fong R, Tan M, Lo M, Arora S, Shah N, Wong SW, Martin T, Wolf J. PMID: 32839138.
      View in: PubMed   Mentions:    Fields:    
    33. Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma. Blood Adv. 2020 07 28; 4(14):3295-3301. Martinez-Lopez J, Wong SW, Shah N, Bahri N, Zhou K, Sheng Y, Huang CY, Martin T, Wolf J. PMID: 32706892; PMCID: PMC7391154.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    34. CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma. Blood Adv. 2020 07 14; 4(13):2899-2911. Ramkumar P, Abarientos AB, Tian R, Seyler M, Leong JT, Chen M, Choudhry P, Hechler T, Shah N, Wong SW, Martin TG, Wolf JL, Roybal KT, Pahl A, Taunton J, Wiita AP, Kampmann M. PMID: 32589729; PMCID: PMC7362346.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    35. Front-line daratumumab in newly diagnosed AL amyloidosis patients. Journal of Clinical Oncology. 2020 May 20; 38(15_suppl):e20569-e20569. Kennedy KV, Shah SN, Wolf WJ, Martin MT, Wong WS. .
      View in: Publisher Site   Mentions:
    36. Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011). Journal of Clinical Oncology. 2020 May 20; 38(15_suppl):8504-8504. Mailankody MS, Jakubowiak JA, Htut HM, Costa CL, Lee LK, Ganguly GS, Kaufman KJ, Siegel SD, Bensinger BW, Cota CM, Doerr DT, DeVries DT, Wong WS. .
      View in: Publisher Site   Mentions:
    37. Investigating macrophage function as a mechanism of resistance to daratumumab in relapsed refractory multiple myeloma patients. Journal of Clinical Oncology. 2020 May 20; 38(15_suppl):e20547-e20547. Kambhampati KS, Wen WK, Sung SV, Wong WS, Martin MT, Wolf WJ, Shah SN, Wiita WA. .
      View in: Publisher Site   Mentions:
    38. Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma. Nat Commun. 2020 04 22; 11(1):1931. Huang HH, Ferguson ID, Thornton AM, Bastola P, Lam C, Lin YT, Choudhry P, Mariano MC, Marcoulis MD, Teo CF, Malato J, Phojanakong PJ, Martin TG, Wolf JL, Wong SW, Shah N, Hann B, Brooks AN, Wiita AP. PMID: 32321912; PMCID: PMC7176739.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    39. Benzodiazepine & Zolpidem Usage in Multiple Myeloma Patients Undergoing Transplantation. Biology of Blood and Marrow Transplantation. 2020 Mar 1; 26(3):s352-s353. Banerjee BR, Dunn DL, Knoche KJ, Lo LM, Dhruva DA, Arora AS, Wong WS, Wolf WJ, Martin MT, Shah SN. .
      View in: Publisher Site   Mentions:
    40. Impact of Plerixafor Use at Different Peripheral Blood CD34+ Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma. Biol Blood Marrow Transplant. 2020 05; 26(5):876-883. Shah EE, Young RP, Wong SW, Damon LE, Wolf JL, Shah ND, Leavitt AD, Loeffler P, Martin TG. PMID: 31785375.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    41. First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial. Blood. 2019 Nov 13; 134(Supplement_1):143-143. Costa CL, Wong WS, Bermúdez BA, de la Rubia dJ, Mateos MM, Ocio OE, Rodríguez-Otero RP, San-Miguel SJ, Li LS, Sarmiento SR, Lardelli LP, Gaudy GA, Boss BI, Kelly KL, Burgess BM, Hege HK, Bensinger BW. .
      View in: Publisher Site   Mentions:
    42. Germline Variation Predicts Treatment Response in Multiple Myeloma. Blood. 2019 Nov 13; 134(Supplement_1):4397-4397. Roter RK, Hu HD, Clay-Gilmour CA, Huntsman HS, Shah SN, Wong WS, Martin MT, Wolf WJ, Binder BM, Kumar KS, Rajkumar RS, Slager SS, Vachon VC, Ziv ZE. .
      View in: Publisher Site   Mentions:
    43. Profiling the Cell Surface Landscape of Proteasome Inhibitor-Treated and -Resistant Multiple Myeloma to Guide Immunotherapy Targeting, Diagnosis, and Biology. Blood. 2019 Nov 13; 134(Supplement_1):1803-1803. Ferguson FI, Lin LY, Tuomivaara TS, Wolf WJ, Martin MT, Wong WS, Shah SN, Driessen DC, Van Ness VB, Wiita WA. .
      View in: Publisher Site   Mentions:
    44. A Single-Center Retrospective Cohort Analysis of Venetoclax in Relapsed/Refractory Multiple Myeloma. Blood. 2019 Nov 13; 134(Supplement_1):5576-5576. Kambhampati KS, Galligan GD, Ledergor LG, Martin MT, Wolf WJ, Wong WS, Shah SN. .
      View in: Publisher Site   Mentions:
    45. Dynamics of Activated CD8+ T-cells and Decreased Osteoclasts in the Tumor Microenvironment are Associated with Clinical Efficacy of Anti-PD-L1 and Anti-CD38 Combination Treatment in Relapsed or Refractory Multiple Myeloma. Blood. 2019 Nov 13; 134(Supplement_1):1907-1907. Raval RA, Cho CH, Green GC, Wassner Fritsch WE, Ma MC, Chang CN, Yan YM, Kockx KM, Shen SS, Huw HL, Balestiere BE, Lipkind LM, Huang HH, Byrtek BM, Colburn CD, Wong WS, Venstrom VJ, Adamkewicz AJ. .
      View in: Publisher Site   Mentions:
    46. DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma. Leukemia. 2020 03; 34(3):938-941. Choudhry P, Mariano MC, Geng H, Martin TG, Wolf JL, Wong SW, Shah N, Wiita AP. PMID: 31595037; PMCID: PMC7214267.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    47. Single cell Dissection of Resistance to anti-BCMA CAR-T cell Therapy. Clinical Lymphoma Myeloma & Leukemia. 2019 Oct 1; 19(10):e25-e26. Ledergor LG, McCarthy ME, Shah SN, Wong WS, Chang CH, Fan FF, Shao SE, Gray GL, Cheung CA, Kwek KS, Bylsma BS, Del Favero DS, Wustrack WR, Spitzer SM, Wolf WJ, Martin MT, Ye YJ, Fong FL. .
      View in: Publisher Site   Mentions:
    48. A single-center retrospective cohort analysis of venetoclax in relapsed/refractory multiple myeloma. Clinical Lymphoma Myeloma & Leukemia. 2019 Oct 1; 19(10):e261. Kambhampati KS, Galligan GD, Shah SN, Wolf WJ, Wong WS, Martin MT. .
      View in: Publisher Site   Mentions:
    49. Prolonged Lenalidomide Maintenace Therapy Improves the Quality and Deep of Response in Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 2019 Oct 1; 19(10):e285-e286. Fernández FR, Martin MT, Shah SN, Wong WS, Tamayo TR, Moraleda MJ, Cabanas CV, Moreno MM, Javier JL, Martín MF, Sanz SA, Cedena CM, Valeri VA, Wolf WJ, Lahuerta LJ, Martinez-Lopez MJ. .
      View in: Publisher Site   Mentions:
    50. Clinical relevance of Minimal residual Disease assessment by NGS in Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 2019 Oct 1; 19(10):e179-e180. Martinez-Lopez MJ, Wong WS, Shah SN, Bahri BN, Zhou ZK, Martin MT, Wolf WJ. .
      View in: Publisher Site   Mentions:
    51. Minimal residual disease clinical monitoring and depth of response in multiple myeloma. Journal of Clinical Oncology. 2019 May 20; 37(15_suppl):8026-8026. Martinez-Lopez MJ, Wong WS, Shah SN, Bahri BN, Zhou ZK, Martin MT, Wolf WJ. .
      View in: Publisher Site   Mentions:
    52. Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline. J Clin Oncol. 2019 05 10; 37(14):1228-1263. Mikhael J, Ismaila N, Cheung MC, Costello C, Dhodapkar MV, Kumar S, Lacy M, Lipe B, Little RF, Nikonova A, Omel J, Peswani N, Prica A, Raje N, Seth R, Vesole DH, Walker I, Whitley A, Wildes TM, Wong SW, Martin T. PMID: 30932732.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    53. Updates on Hematologic Malignancies in the Older Adult: Focus on Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, and Multiple Myeloma. Curr Oncol Rep. 2019 03 08; 21(4):35. Huang LW, Wong SW, Andreadis C, Olin RL. PMID: 30848394; PMCID: PMC6438699.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    54. Retrospective Analysis of Modified Hyper-CVAD Therapy Combined with Proteasome Inhibition for Patients with Multiple Myeloma and Renal Insufficiency or Renal Failure. Blood. 2018 Nov 29; 132(Supplement 1):3236-3236. Galligan GD, Narayan NR, Kim KS, Lazar LA, Tan TM, Fong FR, Lo LM, Shah SN, Arora AS, Wong WS, Martin MT, Wolf WJ. .
      View in: Publisher Site   Mentions:
    55. Daratumumab binds to mobilized CD34+ cells of myeloma patients in vitro without cytotoxicity or impaired progenitor cell growth. Exp Hematol Oncol. 2018; 7:27. Ma X, Wong SW, Zhou P, Chaulagain CP, Doshi P, Klein AK, Sprague K, Kugelmass A, Toskic D, Warner M, Miller KB, Lee L, Varga C, Comenzo RL. PMID: 30356940; PMCID: PMC6192105.
      View in: PubMed   Mentions: 6  
    56. Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p. Clin Lymphoma Myeloma Leuk. 2018 11; 18(11):e493-e499. Wong SW, Hegenbart U, Palladini G, Shah GL, Landau HJ, Warner M, Toskic D, Jaccard A, Hansen T, Bladé J, Cibeira MT, Kastritis E, Dispenzieri A, Wechalekar A, Varga C, Schönland SO, Comenzo RL. PMID: 30104177; PMCID: PMC7441584.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    57. Zoledronic acid-induced orbital inflammation in a patient with multiple myeloma. J Oncol Pharm Pract. 2019 Jul; 25(5):1253-1257. Tan M, Kalin-Hajdu E, Narayan R, Wong SW, Martin TG. PMID: 30005587.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    58. Phase I-b study of isatuximab + carfilzomib in relapsed and refractory multiple myeloma (RRMM). Journal of Clinical Oncology. 2018 May 20; 36(15_suppl):8014-8014. Chari CA, Richter RJ, Shah SN, Wong WS, Jagannath JS, Cho CH, Biran BN, Wolf WJ, Parekh PS, Munster MP, Madduri MD, Campana CF, Martin MT. .
      View in: Publisher Site   Mentions:
    59. Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment. Haematologica. 2018 07; 103(7):1218-1228. Lam C, Ferguson ID, Mariano MC, Lin YT, Murnane M, Liu H, Smith GA, Wong SW, Taunton J, Liu JO, Mitsiades CS, Hann BC, Aftab BT, Wiita AP. PMID: 29622655; PMCID: PMC6029548.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    60. 192 Impact of Plerixafor Use at Different Peripheral Blood CD34+ Cell Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma. Biology of Blood and Marrow Transplantation. 2018 Mar 1; 24(3):s176-s177. Shah SE, Young YR, Wong WS, Martin MT. .
      View in: Publisher Site   Mentions:
    61. A Single-Center Retrospective Cohort Analysis of Venetoclax in Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 2017 Sep 1; 17:s339. Galligan GD, Shah SN, Wolf WJ, Wong WS, Abramovitz AL, Donnelly DB, Narayan NR, Mannis MG, Arora AS, Marsala MA, Cerejo CM, Martin MT. .
      View in: Publisher Site   Mentions:
    62. Primary Amyloidosis With Renal Involvement: Outcomes in 77 Consecutive Patients at a Single Center. Clin Lymphoma Myeloma Leuk. 2017 11; 17(11):759-766. Wong SW, Toskic D, Warner M, Varga C, Moreno-Koehler A, Fein D, Fogaren T, Lee L, Oliver CM, Guthrie SD, Comenzo RL. PMID: 28689003.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    63. A single-center retrospective cohort analysis of venetoclax in post-transplant, relapsed/refractory multiple myeloma. Journal of Clinical Oncology. 2017 May 20; 35(15_suppl):e19514-e19514. Galligan GD, Shah SN, Wolf WJ, Wong WS, Abramovitz AL, Donnelly DB, Narayan NR, Mannis MG, Arora AS, Martin MT. .
      View in: Publisher Site   Mentions:
    64. Stem cell transplantation in patients with systemic AL amyloidosis referred for transplant after suboptimal responses to bortezomib-based initial therapy. Bone Marrow Transplant. 2017 06; 52(6):936-937. Wong SW, Larivee D, Warner M, Sprague KA, Fogaren T, Comenzo RL. PMID: 28394371.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    65. Toxicities, response and survival: Autologous stem cell transplantation for multiple myeloma over 25 years at a single center. Cancer Treatment and Research Communications. 2017; 11:1-5. . View Publication.
    66. Toxicities, response and survival: Autologous stem cell transplantation for multiple myeloma over 25 years at a single center. Cancer Treatment and Research Communications. 2017 Jan 1; 11:1-5. Wong WS, Warner WM, Moreno-Koehler MA, Kritharis KA, Coyle CM, Black BD, Relias RV, Fogaren FT, Lyons LN, Toka TF, Larivee LD, Evens EA, Kao KG, Sprague SK, Klein KA, Miller MK, Comenzo CR. .
      View in: Publisher Site   Mentions:
    67. Impact of Cardiac Stage and Hematologic Response on AL Amyloidosis Patients with Renal Involvement. Blood. 2016 Dec 2; 128(22):2136-2136. Wong WS, Toskic TD, Warner WM, Moreno-koehler MA, Fein FD, Fogaren FT, Lee LL, Oliver OC, Guthrie GS, Comenzo CR. .
      View in: Publisher Site   Mentions:
    68. Risk-Adapted Melphalan and Stem Cell Transplantation after Suboptimal Responses to Bortezomib-Based Initial Therapy in Patients with Systemic Light-Chain Amyloidosis (AL). Blood. 2016 Dec 2; 128(22):5831-5831. Wong WS, Larivee LD, Warner WM, Sprague SK, Fogaren FT, Comenzo CR. .
      View in: Publisher Site   Mentions:
    69. siRNA targeting the κ light chain constant region: preclinical testing of an approach to nonfibrillar and fibrillar light chain deposition diseases. Gene Ther. 2016 10; 23(10):727-733. Ma X, Zhou P, Wong SW, Warner M, Chaulagain C, Comenzo RL. PMID: 27383253.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    70. Beyond the plasma cell: emerging therapies for immunoglobulin light chain amyloidosis. Blood. 2016 05 12; 127(19):2275-80. Weiss BM, Wong SW, Comenzo RL. PMID: 26907632.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    71. The Finding of Del 17p in Marrow Plasma Cells from Patients with Light-Chain Amyloidosis (AL) May Confer a Worse Prognosis. Blood. 2015 Dec 3; 126(23):3049-3049. Wong WS, Palladini PG, Hegenbart HU, Landau LH, Warner WM, Jaccard JA, Avet-Loiseau AH, Hansen HT, Bladé BJ, Cibeira CM, Kastritis KE, Schönland SS, Comenzo CR. .
      View in: Publisher Site   Mentions:
    72. Improvements in Patient Outcomes with Autologous Stem Cell Transplantation for Multiple Myeloma over 25 Years at a Single Center. Blood. 2015 Dec 3; 126(23):5496-5496. Wong WS, Warner WM, Moreno-Koehler MA, Kritharis KA, Coyle CM, Black BD, Relias RV, Fogaren FT, Lyons LN, Toka TF, Larivee LD, Smith SH, Evens EA, Kao KG, Sprague SK, Klein KA, Miller MK, Comenzo CR. .
      View in: Publisher Site   Mentions:
    73. Colchicine Can be an Effective Adjunctive Treatment for Extensive Refractory Chronic-Graft-Versus-Host Disease. Blood. 2015 Dec 3; 126(23):5461-5461. Wong WS, Comenzo CR, Roberts RT, Sprague SK, Miller MK. .
      View in: Publisher Site   Mentions:
    74. CD38 Monoclonal Antibody Therapies for Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2015 Nov; 15(11):635-45. Wong SW, Comenzo RL. PMID: 26443328.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimals
    75. Pre-clinical translational studies of daratumumab in patients with myeloma or AL amyloidosis undergoing autologous hematopoietic stem cell transplantation (SCT). Journal of Clinical Oncology. 2015 May 20; 33(15_suppl):8587-8587. Chaulagain CC, Ma MX, Doshi DP, Wong WS, Klein KA, Sprague SK, Zhou ZP, Comenzo CR. .
      View in: Publisher Site   Mentions:
    76. siRNA for the Ig Light Chain Constant Region Reduces Light Chain Production and Secretion By Human Plasma Cells and in a Murine Xenograft Model. Blood. 2014 Dec 6; 124(21):5722-5722. Ma MX, Zhou ZP, Pilichowska PM, Chaulagain CC, Wong WS, Comenzo CR. .
      View in: Publisher Site   Mentions:
    77. Bone marrow-derived mesenchymal stromal cells from patients with end-stage renal disease are suitable for autologous therapy. Cytotherapy. 2013 Jun; 15(6):663-72. Reinders ME, Roemeling-van Rhijn M, Khairoun M, Lievers E, de Vries DK, Schaapherder AF, Wong SW, Zwaginga JJ, Duijs JM, van Zonneveld AJ, Hoogduijn MJ, Fibbe WE, de Fijter JW, van Kooten C, Rabelink TJ, Roelofs H. PMID: 23419679.
      View in: PubMed   Mentions:
    78. Outcomes in Allogeneic Hematopoietic Stem Cell Transplant Patients = 60 Years of Age with a Novel Reduced Intensity Conditioning Regimen Incorporating Extracorporeal Photopheresis,. Blood. 2011 Nov 18; 118(21):4153-4153. Cossor CF, Wong WS, Miller MK, Black BD, Comenzo CR, Klein KA, Klekar KA, Relias RV, Smith SH, Sprague SK, Switkowski SK, Van Etten VR, Klingemann KH. .
      View in: Publisher Site   Mentions:
    79. MUC1 Knockdown With RNA Interference Inhibits Pancreatic Cancer Growth. J Surg Res. 2009 Nov; 157(1):e39-46. Yuan Z, Liu X, Wong S, Machan JT, Chung MA. PMID: 19482310.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    80. Down-regulation of MUC1 in cancer cells inhibits cell migration by promoting E-cadherin/catenin complex formation. Biochem Biophys Res Commun. 2007 Oct 26; 362(3):740-6. Yuan Z, Wong S, Borrelli A, Chung MA. PMID: 17764657.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCells
    81. A natural mutation in the Tyk2 pseudokinase domain underlies altered susceptibility of B10.Q/J mice to infection and autoimmunity. Proc Natl Acad Sci U S A. 2003 Sep 30; 100(20):11594-9. Shaw MH, Boyartchuk V, Wong S, Karaghiosoff M, Ragimbeau J, Pellegrini S, Muller M, Dietrich WF, Yap GS. PMID: 14500783; PMCID: PMC208803.
      View in: PubMed   Mentions: 44     Fields:    Translation:Animals
    Sandy's Networks
    Concepts (134)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (33)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version v3.1.0-868-g8ba5679c on PROFILES-PWEB02.

    Copyright © The Regents of the University of California